Skip to main content

Published locations for Upadacitinib (Rinvoq) gains psoriatic arthritis as second FDA-approved indication

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Upadacitinib (Rinvoq) gains psoriatic arthritis as second FDA-approved indication

User login

  • Reset your password
  • /content/upadacitinib-rinvoq-gains-psoriatic-arthritis-second-fda-approved-indication
  • /edermatologynews/article/249951/psoriatic-arthritis/upadacitinib-rinvoq-gains-psoriatic-arthritis
  • /familypracticenews/article/249951/psoriatic-arthritis/upadacitinib-rinvoq-gains-psoriatic-arthritis
  • /internalmedicinenews/article/249951/psoriatic-arthritis/upadacitinib-rinvoq-gains-psoriatic
  • /rheumatologynews/article/249951/psoriatic-arthritis/upadacitinib-rinvoq-gains-psoriatic-arthritis
  • /rheumatology/article/249951/psoriatic-arthritis/upadacitinib-rinvoq-gains-psoriatic-arthritis-second
  • /internalmedicine/article/249951/psoriatic-arthritis/upadacitinib-rinvoq-gains-psoriatic-arthritis
  • /dermatology/article/249951/psoriatic-arthritis/upadacitinib-rinvoq-gains-psoriatic-arthritis-second
  • /familymedicine/article/249951/psoriatic-arthritis/upadacitinib-rinvoq-gains-psoriatic-arthritis
  • /psoriatic-arthritis-icymi/article/249951/psoriatic-arthritis/upadacitinib-rinvoq-gains-psoriatic